Acer Therapeutics submitted a new drug application (NDA) seeking the approval of its investigative therapy Edsivo (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS) to the U.S. Food and Drug Administration (FDA). Acer requested priority review and, if granted, the FDA will have 60 days to accept or reject the application.
Pain in patients with Ehlers-Danlos syndrome (EDS) due to arthritis in the joint that attaches the thumb to the hand can be successfully managed with surgery, according to researchers from the Mayo Clinic. Their study, “Thumb carpometacarpal arthritis in patients with Ehlers-Danlos Syndrome: non-operative and operative experiences,” was…
Variants in the AEBP1 gene were identified as the cause of a form of Ehlers-Danlos syndrome in four people from three unrelated families, researchers report. The study, “Bi-allelic Alterations in AEBP1 Lead to Defective Collagen Assembly and Connective Tissue Structure Resulting in a Variant of Ehlers-Danlos Syndrome,” was published in the The…
A new study reveals a lack of awareness among health professionals and pregnant women with Ehlers-Danlos syndrome (EDS) about the condition and the risks associated with it, especially during pregnancy and birth. This lack of awareness could delay access to appropriate care, with detrimental effects for moms-to-be and their babies, according…
Get regular updates to your inbox.